Profil
Jessica Jensen is currently the Executive Vice President-Clinical Development at POINT Biopharma, Inc. in the United States.
Prior to this, she was the Senior Vice President-Clinical Development at Progenics Pharmaceuticals, Inc. from 2018 to 2020.
She will also be the Executive Vice President-Clinical Development at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Jensen has a graduate degree from George Washington University and an undergraduate degree from St. Joseph's University.
Postes actifs de Jessica Jensen
| Sociétés | Poste | Début |
|---|---|---|
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Directeur Technique/Scientifique/R&D | 01/08/2020 |
Anciens postes connus de Jessica Jensen
| Sociétés | Poste | Fin |
|---|---|---|
| POIT BIOP | Directeur Technique/Scientifique/R&D | 27/12/2023 |
| PROGENICS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/08/2020 |
Formation de Jessica Jensen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicines for prostate cancer | Health Technology |
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
POINT Biopharma Global, Inc.
POINT Biopharma Global, Inc. BiotechnologyHealth Technology Develops radioligand therapies for the treatment of cancer | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Commercial Services |
















